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Circulating tumor cells (CTCs) are believed to be responsible for the development of
metastatic disease. Over the last several years there has been a great interest in under-
standing the biology of CTCs to understand metastasis, as well as for the development
of companion diagnostics to predict patient response to anti-cancer targeted therapies.
Understanding CTC biology requires innovative technologies for the isolation of these rare
cells. Here we review several methods for the detection, capture, and analysis of CTCs
and also provide insight on improvements for CTC capture amenable to cellular therapy
applications.
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INTRODUCTION
At its basic definition, cancer is the uncontrolled growth of
cells in the body. Over the past several decades, our under-
standing of cancer has greatly improved and it is now clear
that while the basic definition of cancer holds true, cancer is
an extremely complex disease composed of various molecular
alterations and phenotypic changes. The vast majority of cancer
deaths occur due to metastasis of the primary tumor to distant
sites via circulating tumor cells (CTCs) in the circulation. CTCs
are extremely rare. Over the past 5–10 years, various method-
ologies and platforms have been developed to isolate CTCs for
further characterization and molecular analyses. The emergence
of these technologies have spurred a great interest in CTCs and
researchers and clinicians are realizing the importance of CTCs
in cancer biology as well as their use in cancer diagnosis and
therapy.
While the potential of using CTCs to guide patient treatment
remains promising, the rate-limiting step for widespread use of
CTCs in the clinic remains the lack of robust and high-throughput
technologies for isolation of these rare cells. In fact, in most cases,
most CTC isolation platforms isolate a few to several hundred
CTCs, rendering the functional characterization of these cells
extremely difficult (Maheswaran and Haber, 2010). This review
is not intended to be an exhaustive description of all CTC isola-
tion technologies (for further reading, see Hughes and King, 2012),
but instead will provide a historical framework for CTC isolation
and then focus on current “state of the art” for isolation of viable
CTCs and their potential use in cell therapy.
CTC ISOLATION: FINDING A NEEDLE IN A HAYSTACK
CTCs IN THE CLINIC: HISTORICAL PERSPECTIVE
Great interest in the CTC field was ignited by the introduction
of the CellSearch system (Allard et al., 2004). The CellSearch
system (Veridex, Raritan, NJ, USA) was FDA cleared in Jan-
uary 2004 as a prognostic tool for identifying and counting
CTCs in a blood sample to predict progression-free and overall
survival in patients with metastatic breast cancer. In 2007 and
2008, the CellSearch system was cleared as an aid for monitor-
ing metastatic colorectal and prostate cancer patients, respectively.
The CellSearch system, like many other platforms, relies on the
expressed surface ligand epithelial cellular adhesion molecule
(EpCAM) and immunomagnetic capture to isolate CTCs. CTCs
are subsequently stained and quantified using an antibody against
cytokeratins. Contaminating leukocytes are identified using an
antibody against CD45. CTCs are defined as cytokeratin positive
and CD45 negative.
The CellSearch system made possible, for the first time, the
capture of CTCs in a standardized and highly reproducible fash-
ion within a clinical context. Our group was one of the first to offer
the CellSearch test and to date we have performed approximately
1,500 CellSearch CTC tests on blood from over 150 metastatic can-
cer patients. Our data from this aggregate of patients (unpublished)
is consistent with an earlier study showing that a significant frac-
tion of blood samples tested using the CellSearch system lacked
CTCs (Allard et al., 2004). In addition, CTC outputs from the
CellSearch system typically have low yield and purity (Allard et al.,
2004).
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NEXT GENERATION CTC CAPTURE PLATFORMS
Since the introduction of the CellSearch system, several groups
have invested significant time and resources in developing newer
CTC isolation technologies that overcome the barriers to wide-
spread clinical use associated with the CellSearch system, namely
low yield, low purity, and low throughput. These include method-
ologies that isolate CTCs based on size or other physical properties
(Muller et al., 2005; Wulfing et al., 2006; Mohamed et al., 2009; Tan
et al., 2009). For example, the MagSweeper uses a slowly rotating
magnetic stir bar coated with antibodies against EpCAM to cap-
ture CTCs from unfractionated blood samples, thus improving
throughput due to the elimination of sample preparation steps
(Talasaz et al., 2009). Recent work has used the MagSweeper to
enrich CTCs from patient samples, which were then individually
evaluated for expression levels of 87 genes using a microfluidic-
based qRT-PCR technique. A high degree of expression hetero-
geneity was observed between CTCs, with generally high expres-
sion levels of epithelial-to-mesenchymal transition (EMT)-related
genes such as TGFβ1, vimentin, and CXCR4 (Powell et al., 2012).
Additionally, comparison of four breast cancer cell lines and the
isolated primary CTCs showed particularly disparate expression
profiles, suggesting that cancer cell lines are of dubious utility as a
model for CTC research.
The CTC-chip and herringbone (HB)-chip use antibody-
coated microfluidic devices for capture of EpCAM+ CTCs from
unprocessed whole blood (Nagrath et al., 2007; Maheswaran et al.,
2008; Stott et al., 2010a). The HB-chip is more amenable to man-
ufacturing for high-throughput applications and CTCs captured
on the device are of sufficiently high purity and yield to be inter-
rogated for molecular alterations (Stott et al., 2010b). A recent
observation has been the capture of clusters of CTCs, called cir-
culating tumor microemboli (CTM), from several prostate and
lung cancer patients using the HB-chip (Stott et al., 2010a). Cap-
ture of CTM has also been observed using a slide-based high
definition CTC (HD-CTC) imaging platform (Cho et al., 2012).
Indeed, in a recent study using the “HD-CTC assay” on samples
from 68 patients with metastatic breast, prostate, or pancreatic
cancer, clusters of two or more CTCs were identified in 88% of
patients (Marrinucci et al., 2012). Interestingly, we have made sim-
ilar observations from samples processed on the CellSearch system
(Figure 1). It is unclear what the clinical significance of these CTC
clusters is, although a notable hypothesis suggests that these clus-
ters may serve as a potential mechanism to prevent anoikis thereby
enhancing metastatic potential (Zhang et al., 2008).
The HD-CTC technique is notable in that CTCs in a sample
of blood are enriched only by erythrocyte lysis, and then auto-
mated scanning is used to identify CTCs based on fluorescent
probes. This is important because the only underlying assumption
is that CTCs will not lyse along with erythrocytes in ammonium
chloride solution, which is reasonable. Many other CTC isola-
tion techniques rely on specific surface markers, such as EpCAM
for positive selection or CD45 for negative selection. It has been
shown that EpCAM, while widely expressed across cancer types,
is not universally expressed (Went et al., 2004). Thus CTC capture
based on surface marker expression induces a bias of unknown
consequence. Currently, the HD-CTC technique identifies CTCs
based on cytokeratin expression and CD45 absence,which imposes
FIGURE 1 | Circulating tumor cell clusters captured from a breast
cancer patient using the CellSearch system. (CK, cytokeratin; PE,
phycoerythrin; APC, allophycocyanin; DAPI, 4′,6-diamidino-2-phenylindole).
another bias in that cancer cells that undergo EMT may not pro-
duce cytokeratin (Marrinucci et al., 2012). However, the platform
is amenable to the use of alternate probes that are more universal. A
significant challenge remains for identifying a universal biomarker
for CTCs.
Alternate approaches to CTC isolation are currently in devel-
opment, based on the generally held observation that CTCs are
larger than leukocytes, by processing cell samples through a filter.
A commercially available version, Isolation by Size of Epithe-
lial/Trophoblastic Tumor cells, or ISET (RareCell Diagnostics),
works by simultaneously lysing erythrocytes and fixing remaining
cells in paraformaldehyde, and then perfusing the sample through
a polycarbonate filter with 8µm pores. CTCs thus remain on the
filter, which can be stored prior to analysis of captured CTCs.
Capture sensitivity has been reported to be one CTC per milliliter
of blood (Vona et al., 2000). CTCs have been analyzed by in situ
immunohistochemistry as well as real-time RT-PCR (Pinzani et al.,
2006; Krebs et al., 2012). Interestingly, a recent study found CTM
in 43% of patients studied, and evaluation by Ki67 immunohis-
tochemistry showed that captured CTC were proliferative while
CTM were not (Krebs et al., 2012).
An alternative form of filtration device uses a parylene mem-
brane that allows for formation of pores of controlled size and
shape. In a proof of concept study, a device was constructed to
process whole blood and∼90% recovery was achieved with spiked
samples (Zheng et al., 2007). A promising aspect of this device is
that the filtration was performed within minutes, showing a higher
throughput than most microfluidic methods. An integrated elec-
trode system allows for in situ electrolysis of captured cells to
facilitate rapid harvesting of genetic material. More recently, this
parylene filter system has been used to capture CTCs from patient
samples (Lin et al., 2010).
Our group has developed a technique for capturing CTCs based
on their ability to adhere to endothelium during extravasation
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(Hughes et al., 2012a,b). This technique relies on the binding of
CTCs to microtubes coated with a combination of E-selectin pro-
tein and epithelial specific antibodies absorbed to an immobilized
nanotube layer and perfused under flow. Selectin-mediated cap-
ture mimics the normal and malignant process of cell adhesion to
blood vessels during metastasis and suggests that CTCs captured
using this approach may be more invasive and have undergone
EMT to some degree. The CTCs captured by this approach remain
viable and can be cultured short term to potentiate subsequent
analysis. A halloysite nanotube coating enables >50% purity. It
is interesting to note that in general more CTCs were isolated
and identified using the selectin-based technique compared to
CellSearch on ostensibly identical samples (i.e., two tubes were
drawn from each patient and processed by either technique in
parallel; Figure 2). Indeed, 7 of 12 patient samples were positive
for CTCs using CellSearch, while 12 of 12 were positive using
our device. Other techniques have similarly found significant dis-
cord when using CellSearch on parallel samples; generally more
CTCs are found, suggesting that CellSearch neglects to identify
many CTCs and has a tendency to report false negatives (Lin
et al., 2010; Kirby et al., 2012; Krebs et al., 2012; Marrinucci et al.,
2012).
FIGURE 2 | Circulating tumor cell capture using the
selectin-functionalized microtube device compared to CTC capture of
identical samples using CellSearch.The microtube device was prepared
with or without a halloysite nanotube coating. Figure from Hughes and King
(2012).
THERAPEUTIC APPLICATIONS OF CTCs
The molecular characterization of CTCs may provide opportu-
nities for therapeutic targeting of CTCs or real-time monitoring
of targeted anti-cancer agents (Leversha et al., 2009; Punnoose
et al., 2010). Maheswaran et al. (2008) identified mutations in
epidermal growth factor receptor (EGFR) in CTCs from lung can-
cer patients and showed that after continued anti-EGFR therapy,
a resistance-associated EGFR mutation emerged. In a separate
study using multicolor flow cytometry to rapidly detect and ana-
lyze CTCs following erythrocyte lysis, researchers monitored the
expression of EGFR in its phosphorylated and unphosphorylated
states during the time in which patients were being treated with
different therapies for squamous cell carcinoma of the head and
neck (SCCHN). The researchers found interesting correlations
between different treatment combinations,CTC counts, and EGFR
activation (Tinhofer et al., 2012).
Using multiple CTC isolation platforms, several groups have
examined Her-2 expression on CTCs and shown in some cases
discordance of Her-2 expression between the primary tumor and
CTCs (Hayes et al., 2002; Meng et al., 2004; Punnoose et al., 2010;
Riethdorf et al., 2010). It follows that if CTCs do not express the
same markers as the primary tumor cells, then drugs chosen based
on primary tumor markers will be ineffective against CTCs and
the secondary tumors they seed. Comprehensive molecular pro-
filing of CTCs in the clinic remains hampered by the low yield and
low throughput of most CTC platforms.
The idea of harvesting CTCs from a patient and then studying
these CTCs to rapidly determine the best possible treatment for
that patient is compelling. The feasibility of such a scheme has been
demonstrated to some degree using the geometrically enhanced
differential immunocapture (GEDI) device, which is akin to the
CTC-chip developed by Toner and colleagues (Nagrath et al., 2007)
with altered micropost arrangements to promote collisions with
CTCs based on size (Gleghorn et al., 2010). In the most recent
study using this device, CTCs were captured within the chip and
then treated with different chemotherapeutics in situ to assay drug
susceptibility (Kirby et al., 2012).
Cellular therapy has recently emerged as a promising approach
for treatment of malignancy. Tumor infiltrating lymphocytes or
gene-engineered T cells have been used with some success in
metastatic cancer patients (Restifo et al., 2012). Provenge is the
first active cellular therapy approved by the Food and Drug
administration for the treatment of prostate cancer (Wesley et al.,
2012). Provenge is manufactured by culturing a patient’s periph-
eral blood mononuclear cells (PBMNCs) and antigen presenting
cells with the tumor-associated antigen prostatic acid phosphatase
and granulocyte-macrophage colony stimulating factor. Treat-
ment consists of three infusions at approximately 2-week intervals.
Provenge is the first autologous anti-cancer cell therapy shown to
provide a survival advantage (Wesley et al., 2012).
One intriguing possibility is the ex vivo manipulation of CTCs
for cellular therapy of cancer. The rate-limiting step in this
approach is the low yield associated with many CTC platforms.
In theory, if enough CTCs could be obtained and expanded, they
could be used as a platform for the development of personalized
tumor immunotherapy. An alternative approach for increasing
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the amount of CTCs collected from patients is through leuka-
pheresis (Figure 3). Leukapheresis is a laboratory procedure in
which white blood cells (WBCs or PBMNCs) or peripheral blood
stem cells (PBSCs) are separated from blood. During leukaphere-
sis, a patient’s blood is passed through a machine that removes the
WBCs or PBSCs and then returns the balance of blood back to
the patient. This process usually takes 3 or 4 h to filter the entire
blood supply (approximately 4–6 l). Collected PBSCs may be used
in autologous PBSC transplants to “rescue” the immune system
and blood-forming cells of cancer patients following high-dose
chemotherapy (Montgomery and Cottler-Fox, 2007). Leukaphere-
sis is common in the stem cell transplant setting for treatment
of lymphomas, multiple myeloma, and some solid tumors. The
cell therapy Provenge uses leukapheresis to obtain PBMNCs and
antigen presenting cells for further manipulation (Wesley et al.,
2012).
The product of leukapheresis, termed a leukopak, may also con-
tain CTCs. In theory, one may be able to increase the CTC yield
by filtering the entire blood supply, thereby capturing every CTC
in the body as opposed to the 0.1–0.2% that would be present in a
7.5-ml blood sample. An increase in CTC yield would improve the
diagnostic utility of CTCs and potentially facilitate in vitro drug
screens on CTCs to predict patient response. Our own group has
a Western IRB approved protocol and informed consent for per-
forming leukapheresis on cancer patients in a private, community
based, Phase I oncology clinic. In a recent proof of concept study,
Eifler et al. (2011) showed using spike-in experiments that isola-
tion of CTCs via leukapheresis followed by elutriation to separate
cells based on size, is feasible. Using fluorescence activated cell
sorting (FACS) the authors showed high recovery of CaOV-3 cells
spiked into leukopaks obtained from healthy volunteers (Eifler
et al., 2011). Importantly, no tumor cell events were observed
from leukopaks that had not been spiked with tumor cells. Inter-
estingly, analysis by flow cytometry also revealed a CD45+ and
EpCAM+ dual positive population of cells that occurred at the
highest frequency in the leukopak, and decreased with increasing
elutriation fraction. B-lymphocytes were associated with EpCAM
binding suggesting that leukocyte lineage specific markers should
be used in negative depletion strategies prior to CTC capture,
rather than CD45 which could bias results (Eifler et al., 2011).
Following elutriation, CTCs were further captured using
FACS or EpCAM-coupled magnetic beads (Eifler et al., 2011).
Immunomagnetic bead adsorption recovered 10% of tumor cells
with a median purity of 3.5% (Eifler et al., 2011). EpCAM-coupled
magnetic bead isolation of CTCs from leukopaks is not ideal, in
part because of the cost associated with using such a large amount
of EpCAM antibody.
More recently, several groups are further exploring the poten-
tial of leukapheresis/apheresis for use in CTC isolation. Strat-
mann et al. (2012) obtained blood samples and buffy coat by
apheresis from breast and pancreatic patients (non-metastatic
and metastatic). These samples were then processed using several
CTC technologies. Importantly, all methods were able to detect
CTCs in buffy coat from both non-metastatic and metastatic can-
cer patients and newer CTC isolation platforms (i.e., filer based,
etc.) showed in general a better yield of CTCs in comparison to
CellSearch. In an additional study, Stoecklein et al. (2012) showed
in breast cancer patients that higher CTC detection frequencies
and numbers could be obtained using leukapheresis products as
compared to matched peripheral blood samples from the same
patient. Moreover, captured CTCs were amendable to comparative
genomic hybridization (Stoecklein et al., 2012). Taken together,
these results show the exciting opportunity and potential of using
leukapheresis for CTC isolation. Clearly, newer technologies that
can accommodate large blood volumes are needed for CTC isola-
tion following leukapheresis to be used widespread in the clinic. In
future studies, our group is planning to investigate the feasibility
of processing large volumes using the selectin-based approach.
One of the more ambitious approaches to the incorporation of
CTCs in the design of new cancer therapies is to consider CTCs
as a target for therapy. This is promising considering that 90% of
cancer deaths are caused by metastasis (Wittekind and Neid, 2005).
The disruption of cancer cell dissemination would thus represent
a powerful therapeutic strategy. Photoacoustic flow cytometry has
been developed in recent years that allows for the detection and
ablation of CTCs in vivo. This technology functions by shining a
laser through the skin into a vessel that is up to 3 mm deep and
detecting the acoustic vibrations that result from the absorption of
laser light by target nanoparticles (Zharov et al., 2007). The most
direct application of this technology is for the detection of circulat-
ing melanoma cells, capitalizing on their endogenous expression
of melanin nanoparticles for detection (Nedosekin et al., 2011).
Increasing the incident laser energy can lead to the generation
of heat by the vibrating nanoparticles to a sufficient degree that
FIGURE 3 | Illustration showing potential applications of CTCs following isolation after leukapheresis.
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the flowing melanin-containing cells are ablated (Galanzha et al.,
2009b). This technology can be applied to less photo-distinct CTCs
using targeted gold nanoparticles, for example to target CD44 to
detect and eradicate cancer stem cells (Galanzha et al., 2009a).
Our group has proposed the idea of a shunt device that can
be implanted into the vasculature to capture and eradicate CTCs
in vivo. This device is composed of a selectin-functionalized micro-
tube that will induce the rolling of CTCs along the luminal sur-
face. In one realization of this device, the microtube lumen is
co-functionalized with tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL, also known as Apo2) that signals cell
death to cancer cells via the caspase pathway. A validation study
in vitro achieved a 30% kill rate of cancer cells without compro-
mising leukocyte viability (Rana et al., 2009). Ongoing studies are
evaluating the benefits of manipulating the nanoscale topogra-
phy of the luminal surface to achieve greater CTC eradication. An
alternate version of this device is a microtube shunt that is func-
tionalized with a halloysite nanotube coating which is then coated
with targeted liposomes. Liposomes containing the anti-cancer
drug doxorubicin are coated with polyethylene glycol (PEG) and
E-selectin. Thus flowing cancer cells roll on the selectin-coated
liposomes, and we have shown that these liposomes remain on the
cell surface and are internalized (Mitchell et al., 2012).
CONCLUSION
The true potential of CTCs has yet to be realized because of limits
in technology used to capture these cells and our lack of a complete
understanding of metastasis. This is complicated by the fact that
our understanding of CTCs is subject to the techniques available to
identify and isolate CTCs, and the biases inherent to them. Never-
theless, progress has been made to advance the state of knowledge
and probe the use of CTCs in more active roles than simply enu-
meration. CTCs have the potential to serve as a readily accessible,
transparent window into an individual’s disease. The ideal device
is one that can be used at the point of care to quickly harvest
CTCs and make them available for subsequent analyses. One may
envision how such a scheme would produce personalized cancer
therapies by allowing clinicians to evaluate susceptibilities in the
laboratory, and create tailored therapies for each individual. There
are myriad possibilities if CTCs can be isolated at high-throughput
and purity without bias.
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